Chronic myeloid leukemia is well served by ATP-competitive TKIs, but resistance mutations and cumulative toxicity still push patients through multiple lines. Scemblix (asciminib) attacks the same kinase from a different site.
Unlike the ATP-competitive inhibitors that preceded it, Scemblix binds the ABL myristoyl pocket, making it the first STAMP inhibitor and preserving activity against ATP-site resistance mutations. The oral tablet treats Philadelphia chromosome-positive chronic phase chronic myeloid leukemia in adults previously treated with two or more tyrosine kinase inhibitors, or whose disease carries the T315I mutation.
Scemblix has since expanded into newly diagnosed chronic phase CML, moving it from salvage therapy toward the front line. With no generic competition and activity retained against ATP-site resistance mutations, it is the key differentiated CML asset.
